Date

30 May 2024

Location

NH Koningshof
Veldhoven

Directions

Sessionchairs

  • Dhr. Dr. K.P. (Kevin) Wevers, Maastricht University Medical Center (MUMC+)
  • Dhr. drs. M.I. (Mats) Warmerdam, Leiden University Medical Center (LUMC)

Program

Current status of fluorescence-guided surgery

Dr. J.S.D. (Sven) Mieog, Leiden University Medical Center (LUMC)

That Indocyanine green (ICG) can be used for tissue perfusion assessment or staining of sentinel nodes is now fairly well known among the average surgeon. But what else can we do with ICG? What can be directly applied in practice? And what other fluorescent agents are currently being tested in clinical trials, and can we expect them soon? After this presentation, you will be informed about where fluorescence-guided surgery currently stands and how it will influence future interventions.

Sven Mieog is an HPB surgeon at the LUMC, he obtained his PhD on the clinical translation of fluorescence-guided surgery in 2011. Currently, he is a principal investigator at the 'Green Light Leiden' group and a board member of the DFGS (Dutch Fluorescence Guided Surgery) group.

Results of the AVOID trial; “a Prospective, Phase III, National Multicentre Randomised Controlled Trial using Indocyanine Green Near-infrared fluorescence Bowel Perfusion Assessment to Prevent Anastomotic Leakage in Minimally Invasive Colorectal Surgery”

Dhr. drs. R.A. (Robin) Faber, Leiden University Medical Center (LUMC)

Indocyanine green (ICG) can be used for tissue perfusion assessment. The aim of the AVOID trial was to prospectively assess the clinical benefit of ICG in preventing anastomotic leakage. In this prospective, national, multicenter, randomized controlled phase 3 study, we included 931 patients scheduled for laparoscopic or robotic colorectal surgery in eight participating hospitals in the Netherlands (LUMC, UMCG, HMC, Alrijne, Hagaziekenhuis, MeanderMC, IJsselland, Jeroen Bosch Ziekenhuis, Catharina Ziekenhuis).

Spoiler alert: the results show a reduction in the number of anastomotic leakages in the intervention arm. If you are curious about the specific surgical indications and want to start working with ICG yourself, make sure you attend this talk.  

Robin Faber is a surgical resident (not in training) in the LUMC. In addition to his work as a surgical resident, he is completing his PhD research with the Green Light Leiden research group. In his thesis, he focuses particularly on fluorescence in colorectal surgery, of which the AVOID study is one of the largest multicenter studies in fluorescence-guided surgery worldwide.  


Pitfalls in the use of ICG for perfusion assessment: Challenges and considerations  

Dhr. drs. H.M. (Hugo) Schouw, University Medical Center Groningen (UMCG), Promotor: Prof. dr. S. Kruijff, UMCG

ICG is increasingly used in the clinic for (visual) perfusion assessment with varying results. In the future, quantification of the signal may make 'good' or 'poor' perfusion objectively measurable. Various flow parameters may possibly be correlated with the degree of perfusion. However, various influences such as injection rate, administration of multiple injections, and the length of the infusion line can make reliable quantification challenging. What are the possible solutions? And what should we consider when implementing ICG quantification in different centers?  

Hugo Schouw is conducting a PhD trajectory at the Department of Surgical Oncology and Nuclear Medicine at the UMCG.

Schelto Kruijff is an endocrine surgeon at the UMCG and Karolinska Institutet (Stockholm, Sweden) and conducts extensive research on the use of fluorescence in oncological surgery. In 2022, he was the chairman of the DFGS (Dutch Fluorescence Guided Surgery Group) and is still a board member today.

Time: 14.30 - 15.30

Type: GE

Location: Boszaal